SEARCH

SEARCH BY CITATION

References

  • 1
    Inzucchi S.E., Bergenstal R.M., Buse J.B. et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 13641379.
  • 2
    Cook M.N., Girman C.J., Stein P.P., Alexander C.M., Holman R.R. Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes. Diabetes Care 2005; 28: 9951000.
  • 3
    Cook M.N., Girman C.J., Stein P.P., Alexander C.M. Initial monotherapy with either metformin or sulphonylureas often fails to achieve or maintain current glycaemic goals in patients with Type 2 diabetes in UK primary care. Diabet Med 2007; 24: 350358.
  • 4
    Standl E. The importance of beta-cell management in type 2 diabetes. Int J Clin Pract Suppl 2007; 153: 1019.
  • 5
    Bennett W.L., Maruthur N.M., Singh S. et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med 2011; 154: 602613.
  • 6
    Neumiller J.J., White J.R. Jr., Campbell R.K. Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus. Drugs 2010; 70: 377385.
  • 7
    Defronzo R.A. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009; 58: 773795.
  • 8
    Devineni D., Morrow L., Hompesch M. et al. Canagliflozin improves glycemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes Metab 2012; 14: 539545.
  • 9
    Liang Y., Arakawa K., Ueta K. et al. Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. PLoS One 2012; 7: e30555.
  • 10
    Nomura S., Sakamaki S., Hongu M. et al. Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus. J Med Chem 2010; 53: 63556360.
  • 11
    Rosenstock J., Aggarwal N., Polidori D. et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care 2012; 35: 12321238.
  • 12
    Sha S., Devineni D., Ghosh A. et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab 2011; 13: 669672.
  • 13
    Inagaki N., Kondo K., Iwasaki T. et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2 (SGLT2) improves glycemic control and reduces body weight in Japanese type 2 diabetes mellitus (T2DM) (Abstract 0999-P). Diabetes 2011; 60(Suppl. 1): A274.
  • 14
    Polidori D., Sha S., Mudaliar S. et al. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion (Abstract 79-OR). Diabetes 2012; 61(Suppl. 1): A22.
  • 15
    Stein P., Berg J.K., Morrow L. et al. Canagliflozin (CANA), a sodium glucose co-transporter 2 (SGLT2) inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes mellitus (T2DM) by a non-renal mechanism (Abstract 84-OR). Diabetes 2012; 61(Suppl. 1): A24.
  • 16
    Klein S., Sheard N.F., Pi-Sunyer X. et al. Weight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies: a statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the American Society for Clinical Nutrition. Diabetes Care 2004; 27: 20672073.
  • 17
    Diabetes Prevention Program Research Group. Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care 2012; 35: 731737.
  • 18
    Polidori D., Zhao Y., Sha S., Canovatchel W. Canagliflozin treatment improves beta cell function in subjects with type 2 diabetes (Abstract 646-P). Diabetes 2010; 59(Suppl. 1).
  • 19
    Wajchenberg B.L. Clinical approaches to preserve beta-cell function in diabetes. Adv Exp Med Biol 2010; 654: 515535.
  • 20
    Nicolle L.E., Capuano G., Ways K., Usiskin K. Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study. Curr Med Res Opin 2012; 28: 11671171.
  • 21
    Nyirjesy P., Zhao Y., Ways K., Usiskin K. Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor. Curr Med Res Opin 2012; 28: 11731178.
  • 22
    Ferrannini E., Ramos S.J., Salsali A., Tang W., List J.F. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 2010; 33: 22172224.